Arcellx

ACLX

시가총액 US$67.3억

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and.

Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kennedy-Wilson Holdings, Inc. (NYSE: KW)'s  sale to consortium led by William McMorrow, Chairman and Chief Executive Officer of Kennedy-Wilson, and certain other senior executives of Kennedy-Wilson, together with Fairfax Financial Holdings Limited, for $10.90 per share in cash. If you are a Kennedy-Wilson shareholder,  click here to learn more about your rights and options.

As of March 18, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Cormorant Asset Management sold 775,000 Arcellx shares in the fourth quarter. The fund's quarter-end position value in Arcellx decreased by $63.63 million, reflecting a complete position sale during the period.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arcellx, Inc. (NasdaqGS: ACLX) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of Arcellx will receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. KSF is seeking to deter.

As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

During the quarter, Baron Health Care Fund added seven new positions and exited ten positions, bringing the number of positions in the Fund to 43. We bought shares of Arcutis Biotherapeutics, Inc., a biotechnology company that sells Zoryve cream and foam for the treatment of autoimmune dermatologic conditions. We sold Cidara Therapeutics, Inc. after the company announced it was being acquired by Merck for a substantial premium.

Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing guidance for the next two quarters.

ACLX share prices have soared nearly 75% in 2026 due to the recent announcement that Arcellx will be acquired. The acquisition will turn Arcellx back private, after only being on the stock market for four years.